Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. [electronic resource]
Producer: 20190128Description: 2155-2163 p. digitalISSN:- 1432-0428
- Adipose Tissue -- metabolism
- Asian People
- Aspartate Aminotransferases -- metabolism
- Benzhydryl Compounds -- therapeutic use
- Diabetes Mellitus, Type 2 -- drug therapy
- Female
- Glucosides -- therapeutic use
- Humans
- Hypoglycemic Agents -- therapeutic use
- Liver -- drug effects
- Male
- Non-alcoholic Fatty Liver Disease -- metabolism
- Research Design
- Sodium-Glucose Transporter 2 -- metabolism
- Sodium-Glucose Transporter 2 Inhibitors -- therapeutic use
- Sulfonylurea Compounds -- therapeutic use
- Time Factors
- Transaminases -- metabolism
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.